Real-world evidence — data generated outside the controlled conditions of clinical trials, from electronic health records, claims databases, registries, and patient-reported outcomes — has moved from a post-marketing afterthought to a core component of regulatory and commercial decision-making. Regulatory agencies are increasingly willing to accept real-world data to support label expansion, post-marketing commitment fulfilment, and comparative effectiveness claims. The organisations positioned to extract maximum value from this regulatory evolution are those that have built the semantic infrastructure to link real-world data to their clinical trial knowledge base.
The Semantic Integration Challenge
Linking real-world data to clinical trial evidence requires resolving fundamental differences in how the two types of data represent clinical concepts. Clinical trial data uses protocol-defined endpoints, study-specific eligibility logic, and carefully curated adverse event coding. Real-world data uses whatever coding conventions the source system employed — typically ICD codes for diagnoses, NDC or RxNorm codes for medications, and LOINC codes for laboratory values — applied at the granularity appropriate for billing or EHR documentation rather than clinical research. A semantic layer that maps real-world coding concepts to the ontological identifiers used in the clinical trial knowledge base makes the two evidence streams comparable.
Analytical Capabilities Enabled by Integration
Once real-world data is semantically integrated with the clinical trial evidence base, several analytical capabilities become available that are not possible with either data type alone. Drug effectiveness in subpopulations that were excluded from clinical trials — elderly patients, those with significant comorbidities, patients in real practice settings — can be estimated using the same exposure and outcome definitions used in trials. Long-term safety signals that emerge beyond trial follow-up periods can be detected and characterised. Comparative effectiveness against real-world treatment alternatives — rather than against placebo — can be assessed.
The Regulatory Opportunity
The regulatory opportunity for organisations with well-structured real-world evidence programmes is substantial. Post-marketing commitments that currently require long, expensive registry studies can be fulfilled more efficiently from well-governed real-world data sources when the data is demonstrably aligned with the relevant ontological standards. Label expansion filings supported by real-world evidence packages that are semantically linked to the original approval's clinical knowledge base provide regulators with a coherent evidentiary narrative that strengthens the submission.
